Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model
Open Access
- 11 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e46746
- https://doi.org/10.1371/journal.pone.0046746
Abstract
Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation is thought to be the single most effective way of reducing the economic burden of COPD. The impact of other strategies such as interventions that predict risk of disease, reduce progression of disease, or reduce exacerbations has not been systematically studied. We estimated the economic and clinical burden of COPD over the next 25 years in Canada and the impact of three potential interventions (screening test for predisposition to COPD, new drugs to avoid progression into more severe disease stages, and predictive test for exacerbations) on COPD burden. Using a dynamic simulation model, we projected the total burden of COPD (cost, morbidity, and mortality) from 2011 to 2035 using the population of Canada as a case study. The model stratified population based on sex, age, smoking status, respiratory symptoms, and their COPD stage. The cost and quality adjusted life years (QALYs) associated with each intervention were estimated. The model indicates that annual societal cost of COPD is $4.52 billion (B) Canadian dollars in 2011 and will reach $3.61B ($7.33B undiscounted) per year in 2035. Over the next 25 years, COPD will be responsible for approximately $101.4B in societal costs ($147.5B undiscounted) and 12.9 million QALYs lost (19.0 million undiscounted). Our results suggested that the best strategy to reduce the financial burden of COPD is by reducing exacerbations. Smoking cessation, while it is the cornerstone of COPD prevention, has only a modest effect in attenuating the financial burden of COPD over the next 25 years in Western countries such as Canada. Our data suggest that any intervention that can reduce the number of exacerbations has a substantial impact on morbidity and costs of COPD and should be considered in conjunction with the ongoing efforts to reduce smoking rates.Keywords
This publication has 33 references indexed in Scilit:
- Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary DiseaseValue in Health, 2011
- Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population studyThe Lancet, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Trends in Asthma Prevalence and Incidence in Ontario, Canada, 1996-2005: A Population StudyAmerican Journal of Epidemiology, 2010
- Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPDThorax, 2010
- The Potential Value of Biomarkers in Diagnosis and Staging of COPD and ExacerbationsSeminars in Respiratory and Critical Care Medicine, 2010
- Diagnostic accuracy of spirometry in primary careBMC Pulmonary Medicine, 2009
- The Direct Medical Costs of Undiagnosed Chronic Obstructive Pulmonary DiseaseValue in Health, 2008
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, CanadaMedical Care, 2000